A Phase 1 interventional study of Baricitinib and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants. The study will measure how the body absorbs, breaks down and gets rid of baricitinib. The study will last about 20 days, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
Drug: Baricitinib
4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
Drug: Baricitinib
10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
Drug: Baricitinib
Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
Drug: Placebo
Administered orally.
Also known as: LY3009104
Administered orally.
Number of Participants With One or More Clinically Significant Event(s)
Clinically significant events were defined as a moderate to severe adverse event, abnormal clinical sign, or clinical laboratory finding that may pose risk to the well-being of the participant. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
Time frame: Baseline through Study Completion (up to Day 20)
Pharmacokinetics(PK): Maximum Concentration (Cmax) of Baricitinib
Maximum observed drug concentration for single dose and Cmax as steady date for multiple dosing.
Time frame: Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib
Area under the concentration versus time curve from zero to infinity (AUC0-inf) during single dose and area under the concentration versus time curve (AUCtau,ss) during multiple dose of baricitinib at steady state.
Time frame: Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose
| Milestone | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|---|
| Started | 8 | 8 | 9 | 8 |
| Received at least one dose of study drug | 8 | 8 | 9 | 8 |
| Completed | 6 | 8 | 8 | 8 |
| Not completed | 2 | 0 | 1 | 0 |
| Withdrew: Physician and sponsor decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
| Milestone | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|---|
| Started | 6 | 8 | 8 | 8 |
| Completed | 6 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Clinically significant events were defined as a moderate to severe adverse event, abnormal clinical sign, or clinical laboratory finding that may pose risk to the well-being of the participant. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
| Participants | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|---|
| Number of Participants With One or More Clinically Significant Event(s) | 4 | 0 | 2 | 4 |
Maximum observed drug concentration for single dose and Cmax as steady date for multiple dosing.
| nanogram per milliliter (ng/mL) | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|
| Single Dose Day 1 | 24.3 ± 17 | 47.8 ± 42 | 147 ± 28 |
| Multiple Dose Day 10 | 28.0 ± 24 | 48.0 ± 28 | 136 ± 17 |
Area under the concentration versus time curve from zero to infinity (AUC0-inf) during single dose and area under the concentration versus time curve (AUCtau,ss) during multiple dose of baricitinib at steady state.
| nanogram * hour per milliliter (ng*h/mL) | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|
| Single Dose Day 1 | 139 ± 12 | 270 ± 17 | 777 ± 9 |
| Multiple Dose Day 10 | 145 ± 12 | 265 ± 18 | 771 ± 14 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/8 (0%) | 4/8 (50%) |
| 2mg Baricitinib | — | 0/8 (0%) | 1/8 (12.5%) |
| 4mg Baricitinib | — | 0/9 (0%) | 2/9 (22.2%) |
| 10mg Baricitinib | — | 0/8 (0%) | 4/8 (50%) |
| Event | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/8 | 0/8 | 1/9 | 2/8 |
| Electrocardiogram abnormalInvestigations | 2/8 | 0/8 | 0/9 | 0/8 |
| Aspartate aminotransferase increasedInvestigations | 1/8 | 0/8 | 1/9 | 1/8 |
| Blood bilirubin increasedInvestigations | 0/8 | 0/8 | 0/9 | 1/8 |
| Blood creatine phosphokinase increasedInvestigations | 0/8 | 1/8 | 0/9 | 0/8 |
| Blood triglycerides increasedInvestigations | 0/8 | 0/8 | 0/9 | 1/8 |
| Blood uric acid increasedInvestigations | 0/8 | 1/8 | 0/9 | 0/8 |
| Protein urine presentInvestigations | 1/8 | 0/8 | 0/9 | 0/8 |
| HypotensionVascular disorders | 1/8 | 0/8 | 0/9 | 0/8 |
| Orthostatic hypotensionVascular disorders | 0/8 | 0/8 | 0/9 | 1/8 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib | Total |
|---|---|---|---|---|---|
| Mean | 26.6 ± 5.4 | 30.8 ± 7.3 | 26.6 ± 3.5 | 27.6 ± 6.7 | 27.8 ± 5.8 |
| Sex: Female, Male(Participants) | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 9 | 8 | 33 |
| Race (NIH/OMB)(Participants) | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 9 | 8 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib | Total |
|---|---|---|---|---|---|
| China | 8 | 8 | 9 | 8 | 33 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Placebo | 2mg Baricitinib | 4mg Baricitinib | 10mg Baricitinib | Total |
|---|---|---|---|---|---|
| Mean | 22.34 ± 1.21 | 22.15 ± 1.75 | 21.87 ± 1.28 | 21.68 ± 1.39 | 22.01 ± 1.38 |
The record gives a start of May 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib